The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Targeting Breast Cancer Stem Cells to Overcome Treatment Resistance
Open accessAbstract
Despite advances in breast cancer diagnosis and treatment, many patients still fail therapy, resulting in disease progression, recurrence, and reduced overall survival. Historically, much focus has been put on the intrinsic subtyping based in the presence (or absence) of classical immunohistochemistry (IHC) markers such as estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-related protein (HER2). However, it is widely understood that tumors are composed of heterogeneous populations of cells with a hierarchical organization driven by cancer stem cells (CSCs). In breast tumors, this small population of cells displaying stem cell properties is known as breast CSCs (BCSCs). This rare population exhibit a CD44+/CD24−/low phenotype with high ALDH activity (ALDH+), and possesses higher tolerability to chemotherapy, hormone therapy, and radiotherapy and is able to reproduce the bulk of the tumor after reduction of cell populations sensitive to first-line therapy leading to disease relapse. In this review, we present special attention to BCSCs with future directions in the establishment of a therapy targeting this population. Drugs targeting the main BCSCs signaling pathways undergoing clinical trials are also summarized.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Samanta, D., Gilkes, D. M., Chaturvedi, P., Xiang, L., & Semenza, G. L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1421438111 · Cited by 460
RetractedSlamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice
Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., Minden, M., Paterson, B., Caligiuri, M. A., & Dick, J. E. (1994) · Nature · doi:10.1038/367645a0 · Cited by 4,783
Wnt signal transduction pathways
Komiya, Y., & Habas, R. (2008) · Organogenesis · doi:10.4161/org.4.2.5851 · Cited by 1,528
Ishimoto, T., Nagano, O., Yae, T., Tamada, M., Motohara, T., Oshima, H., Oshima, M., Ikeda, T., Asaba, R., Yagi, H., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.038 · Cited by 1,192 · cited 1×
“BCSCs expressing CD44+/CD24- also have the capacity to reduce intracellular reactive oxygen species (ROS) levels induced in ionizing radiation, by overexpression of radical scavenger, by increasing the reduced glutathione synthesis though the Sx(-) antiporter system and by enhanced NADH and FADH2 products generated fr…”
Backgroundp57 is required for quiescence and maintenance of adult hematopoietic stem cells
Matsumoto, A., Takeishi, S., Kanie, T., Susaki, E., Onoyama, I., Tateishi, Y., Nakayama, K., & Nakayama, K. I. (2011) · Cell stem cell · doi:10.1016/j.stem.2011.06.014 · Cited by 329
Zou, P., Yoshihara, H., Hosokawa, K., Tai, I., Shinmyozu, K., Tsukahara, F., Maru, Y., Nakayama, K., Nakayama, K. I., & Suda, T. (2011) · Cell stem cell · doi:10.1016/j.stem.2011.07.003 · Cited by 289 · cited 2×
“The quiescent state of BCSCs might be altered by targeting the cyclin-dependent kinase inhibitors p57KIP2, p27KIP1, and p18INK4c as seen in hematopoietic (HCSs) [64,83] and chronic myeloid leukemia [84] stem cells.”
BackgroundXiang, L., Gilkes, D. M., Chaturvedi, P., Luo, W., Hu, H., Takano, N., Liang, H., & Semenza, G. L. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-013-1102-5 · Cited by 114 · cited 1×
“The stimulation of HIF-1α induced in hypoxia conditions that promotes BCSC development may be targeted by HIF-1α inhibitors such as ganetespib (a second-generation HSP90 inhibitor) [90] overcoming chemoresistance, both in vitro and in vivo [76].”
Background
Cited by
Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook
Obidiro, O., Battogtokh, G., & Akala, E. O. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071796 · Cited by 511
Targeting breast cancer and their stem cell population through AMPK activation: novel insights
Uprety, B., & Abrahamse, H. (2022) · Cells · doi:10.3390/cells11030576 · Cited by 33
Metadata
- Authors
- Palomeras, S., Ruiz-Martínez, S., & Puig, T.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2018-08-30
- Volume
- 23
- Issue
- 9
- Pages
- 2193
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W2888944160
- Cited by
- 163
- References
- 8
- FWCI
- 5.90
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.